Literature DB >> 19357523

Hepatitis C and hepatitis B-related mortality in Spain.

Ana García-Fulgueiras1, Rocío García-Pina, Consuelo Morant, Visitación García-Ortuzar, Ricard Génova, Elena Alvarez.   

Abstract

BACKGROUND: Although hepatitis C and hepatitis B virus (HCV/HBV) infections are an important health problem worldwide, their burden of disease (BoD) taking into account their chronic consequences, cirrhosis, and hepatocellular carcinoma (HCC), is still unknown. Our aim was to assess the total number of deaths attributable to these viruses in Spain and the years of life lost, first component of the disability adjusted life years, a comparative index of BoD.
METHODS: We selected the International Classification of Diseases-Tenth Revision specific codes related to HCV/HBV. For unspecified cirrhosis and HCC, the attributable fraction of mortality was assessed in two steps: literature review and expert panel. Deaths in Spain in 2000 were obtained from the National Statistics Institute. Years of life lost were calculated using the estimated mortality and life expectancies (Princeton Model Life Table).
RESULTS: HCV could have caused around 70% of HCC deaths and 50% of cirrhosis mortality in Spain in 2000 (60% HCC, 40% cirrhosis with HCV lower estimate). For HBV these proportions are 10 and 13%, respectively. We estimated 4342 HCV-related deaths and 877 HBV-related deaths in Spain in 2000, globally 1.5% of total deaths in Spain that year. Mortality by cirrhosis and HCC represented most of these viral-related deaths. Attributable mortality in AIDS patients was also estimated.
CONCLUSION: HCV leads the list of infectious disease-related mortality in Spain in 2000, doubling the AIDS mortality even if lower HCV attributable fractions are considered. Exclusion of cirrhosis and HCC-related mortality severely underestimates the BoD attributable to HCV/HBV. Improving early diagnosis and access to treatment could have an important impact on mortality because of hepatitis virus in the next decades.

Entities:  

Mesh:

Year:  2009        PMID: 19357523     DOI: 10.1097/MEG.0b013e328313139d

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Attributable deaths of liver cancer in China.

Authors:  Maomao Cao; Chao Ding; Changfa Xia; He Li; Dianqin Sun; Siyi He; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2021-08-31       Impact factor: 5.087

Review 2.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 3.  Liver transplantation for viral hepatitis in 2015.

Authors:  Alberto Ferrarese; Alberto Zanetto; Martina Gambato; Ilaria Bortoluzzi; Elena Nadal; Giacomo Germani; Marco Senzolo; Patrizia Burra; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  Labour productivity losses caused by premature death associated with hepatitis C in Spain.

Authors:  Juan Oliva-Moreno; Luz M Peña-Longobardo; Sonia Alonso; Antonio Fernández-Bolaños; María Luisa Gutiérrez; Álvaro Hidalgo-Vega; Elsa de la Fuente; Conrado M Fernández-Rodríguez
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-06       Impact factor: 2.566

Review 5.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

6.  Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.

Authors:  R Boix; R Cano; P Gallego; F Vallejo; R Fernández-Cuenca; I Noguer; A Larrauri
Journal:  BMC Health Serv Res       Date:  2017-07-05       Impact factor: 2.655

Review 7.  Hepatitis B virus infection: Defective surface antigen expression and pathogenesis.

Authors:  Chun-Chen Wu; Ying-Shan Chen; Liang Cao; Xin-Wen Chen; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

8.  The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries.

Authors:  Jeffrey Vietri; Girish Prajapati; Antoine C El Khoury
Journal:  BMC Gastroenterol       Date:  2013-01-17       Impact factor: 3.067

9.  Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain.

Authors:  Claudia Palladino; Ifeanyi Jude Ezeonwumelu; Irene Mate-Cano; Pedro Borrego; Paula Martínez-Román; Sonia Arca-Lafuente; Salvador Resino; Nuno Taveira; Verónica Briz
Journal:  Sci Rep       Date:  2020-08-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.